November 9, 2020

10 Nov 20 | IL | Prestige BioPharma, Teva Israel | Prestige BioPharma and Teva Israel announce they have entered into an exclusive partnership and supply agreement for Prestige's Tuznue® (trastuzumab biosimilar) in Israel. Under the agreement, Prestige is responsi...

Significant biosimilar activities this week include:

  • 15 Oct 20: Henlius and Essex announced they have entered into a co-development and exclusive license agreement for HLX04 (proposed bevacizumab biosimilar). Under the agreement, Essex will be granted an exclusive l...

Significant biosimilar activities this week include:

  • 23 April 2020: Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02.

  • 28 April 2020: Mylan and Biocon launched Fulphila® (pegfilgrastim) in Canada. Ful...

Significant biosimilar activities this week include:

  • On 09 March 2020, the FDA and FTC held a public workshop to further their efforts in creating a better biosimilar landscape in the US. The Centre for Biosimilars reported that topics discussed at the conference in...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags